2017
Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubovski E, Bloch MH. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology 2017, 43: 325-333. PMID: 28849779, PMCID: PMC5729569, DOI: 10.1038/npp.2017.194.Peer-Reviewed Original ResearchConceptsLiebowitz Social Anxiety ScaleSocial anxiety disorderAnxiety disordersSocial Anxiety ScaleSelf-reported anxietySocial phobia symptomsRatings of anxietyPotent N-methyl-d-aspartate receptor antagonistPhobia symptomsAnxiety symptomsAnxiety ScaleImpact of ketamineInitial evidenceAnxietyTreatment respondersVAS anxietyPlacebo-controlled crossover trialRatingsDisordersLinear mixed modelsPrior studiesConcept trialInadequate symptom reliefRandom orderMixed models
2010
Predictors of early adulthood quality of life in children with obsessive–compulsive disorder
Palermo SD, Bloch MH, Craiglow B, Landeros-Weisenberger A, Dombrowski PA, Panza K, Smith ME, Peterson BS, Leckman JF. Predictors of early adulthood quality of life in children with obsessive–compulsive disorder. Social Psychiatry And Psychiatric Epidemiology 2010, 46: 291-297. PMID: 20191262, PMCID: PMC3645906, DOI: 10.1007/s00127-010-0194-2.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderEarly adulthoodOCD symptomsImpaired Functioning ToolMethodsA longitudinal cohort studyLongitudinal cohort studyResultsForty-two percentSeverity of OCDAverage followClinical predictorsCohort studyPoor QoLResidual impairmentMild impairmentQoLSymptomsObjectivesThe goalAnxiety symptomsAdulthoodChildrenQoL.ChildhoodHoarding symptomsImpairmentDisorders